Literature DB >> 1428526

Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor.

J Bongers1, E P Heimer, T Lambros, Y C Pan, R M Campbell, A M Felix.   

Abstract

Products of the degradation of human growth hormone-releasing factor (GRF) in aqueous solutions (15-200 microM) have been isolated and fully characterized. The cleavage product, GRF(4-44)-NH2, and the isomerization product, [beta-Asp3]GRF(1-44)-NH2, from the degradation of GRF(1-44)-NH2 in acidic solution and the corresponding products, GRF(4-29)-NH2 and [beta-Asp3]GRF(1-29)-NH2, from the degradation of GRF(1-29)-NH2 have been isolated and characterized. The products, [beta-Asp8]GRF(1-44)-NH2 and [Asp8]GRF(1-44)-NH2, from the deamidation of GRF(1-44)-NH2 at pH 8.0 and the corresponding products, [beta-Asp8]GRF(1-29)-NH2 and [Asp8]GRF(1-29)-NH2, from the deamidation of GRF(1-29)-NH2 have been isolated and characterized. All the degradation products of GRF(1-44)-NH2 and GRF(1-29)-NH2 were evaluated for biological activity and found to have much lower in vitro potencies than the parent peptides. Degradation occurs at Asp3 and Asn8 and the kinetics of these various transformations versus pH and temperature have been studied. GRF is most stable at pH 4-5. At pH below the pKa of the Asp3 side-chain (pH less than 4), cleavage at Asp3-Ala4 is the major route of degradation. For pH greater than 4, isomerization of Asp3 to beta-Asp3 (iso-Asp3) predominates. The rates of cleavage and isomerization are simple first order and vary with pH, independent of buffer concentration, such that the protonated (COOH) form of Asp3 undergoes cleavage while the ionized (COO-) form isomerizes. The more rapid deamidation of Asn8 to generate beta-Asp8 and Asp8 in about a 4:1 ratio, presumably via a cyclic imide intermediate, occurs at pH greater than or equal to 5 and is general base-catalyzed. Evidence was also obtained for direct hydrolysis of protonated Asn8 in GRF(1-29)-NH2 at pH less than or equal to 2 to give exclusively [Asp8]GRF(1-29)-NH2. The deamidation of Asn8 in GRF(1-29)-NH2 at pH 8.0, 22-55 degrees C, is relatively insensitive to temperature for T less than 37 degrees C, possibly due to conformational constraints. Asp25 and Asn35 are sterically, conformationally, or otherwise hindered with respect to these changes as no degradation at these sites was observed under the conditions employed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1428526     DOI: 10.1111/j.1399-3011.1992.tb01596.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  6 in total

1.  Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.

Authors:  Yi Wang; Xiaojuan Li; Yan-Hui Liu; Daisy Richardson; Huijuan Li; Mohammed Shameem; Xiaoyu Yang
Journal:  MAbs       Date:  2016-09-06       Impact factor: 5.857

Review 2.  Predicting protein decomposition: the case of aspartic-acid racemization kinetics.

Authors:  M J Collins; E R Waite; A C van Duin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-01-29       Impact factor: 6.237

3.  Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: effects of the solvent dielectric.

Authors:  T V Brennan; S Clarke
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

4.  Aqueous stability of human epidermal growth factor 1-48.

Authors:  R I Senderoff; S C Wootton; A M Boctor; T M Chen; A B Giordani; T N Julian; G W Radebaugh
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

5.  Chemical pathways of peptide degradation. VII. Solid state chemical instability of an aspartyl residue in a model hexapeptide.

Authors:  C Oliyai; J P Patel; L Carr; R T Borchardt
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

6.  Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

Authors:  Jozsef L Varga; Andrew V Schally; Judit E Horvath; Magdolna Kovacs; Gabor Halmos; Kate Groot; Gabor L Toller; Zoltan Rekasi; Marta Zarandi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-30       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.